An Exploratory Cost-Effectiveness Analysis of Immune Therapy in Delaying the Initiation of Automated Insulin Delivery Systems in Type 1 Diabetes
Authors' conclusion
Preventive ATG therapy followed by AID after T1D onset can be a potentially cost-effective approach.
Study context
- Population
- Simulated individuals at risk of T1D (model-based)
- Comparison
- Six prevention-treatment strategies: preventive immune therapy (teplizumab, antithymocyte globulin (ATG) or none) combined with AID or conventional insulin management
- Outcome
- Cost-effectiveness: lifetime costs (payer perspective) and QALYs
- Follow-up
- Lifetime
Methodological detailsmicrosimulation modelling study, exploratory, payer perspective, lifetime horizon
- Microsimulation modelling study
- Exploratory
- Payer perspective
- Lifetime horizon
Main finding
As reported in the abstract
Cost-effectiveness (lifetime costs, QALYs) of six prevention-treatment strategies
QALY difference
0.25 QALYs
more quality-adjusted life years (QALYs) with teplizumab + AID
Additional cost
$153,670
higher cost with teplizumab + AID
Incremental cost-effectiveness ratio
$369,890/QALY
Cost-effectiveness (lifetime costs, QALYs) of six prevention-treatment strategies
- Lifetime costs of the most cost-effective strategy (preventive ATG followed by AID)
- $394,250
- QALYs of the most cost-effective strategy (preventive ATG followed by AID)
- 19.13
Original publication
An Exploratory Cost-Effectiveness Analysis of Immune Therapy in Delaying the Initiation of Automated Insulin Delivery Systems in Type 1 Diabetes. Diabetes Technol Ther. Published 12 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →